AN2 Therapeutics, a biopharmaceutical company specializing in boron chemistry-based therapeutics, has secured continued research funding from the Bill & Melinda Gates Foundation. This grant will support their ongoing efforts to discover and develop new tuberculosis (TB) and malaria treatments. These infectious diseases pose a significant global health threat, causing nearly 2 million deaths annually.
The grant will specifically focus on developing novel aminoacyl-tRNA synthetase inhibitors, leveraging AN2’s proprietary boron chemistry platform. This innovative approach aims to address the growing challenge of drug resistance and shorten treatment durations for TB and malaria. AN2’s expertise in this area is highlighted by their previous development of successful boron-based drugs like epetraborole (for NTM and melioidosis), tavaborole (an FDA-approved antifungal), and ganfeborole (currently in development for TB by GSK).
This funding continuation underscores the potential of AN2’s boron chemistry platform in creating novel therapies for critical global health challenges. By targeting leucyl-tRNA synthetase, a validated target in Mycobacteria and other disease-causing organisms, AN2 aims to develop effective treatments for TB, nontuberculous Mycobacteria lung disease, and other infectious diseases.
AN2 Therapeutics, with its pipeline of boron-based compounds, is committed to addressing unmet medical needs in various therapeutic areas, including Chagas disease, NTM, melioidosis, infectious diseases, and oncology.
